FDA Advisory Panel Rejects AstraZeneca’s Camizestrant Over Trial-Design Concerns

On May 1 2026 the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 6-3 against recommending AstraZeneca’s oral selective estrogen-receptor degrader camizestrant for HR+/HER2- metastatic breast cancer with an ESR1 mutation. The decision followed the Phase 3 SERENA-6 trial, presented in 2025, which showed a 56 % reduction in risk of disease progression or death and a median progression-free survival of 16 months versus 9.2 months on standard therapy. Overall-survival data remain immature. AstraZeneca expects camizestrant to generate up to $5 billion in peak sales toward its $80 billion 2030 target.

BioSpace

AstraZeneca expressed disappointment but said it remains confident and will continue discussions with the FDA (Susan Galbraith, EVP Oncology Haematology R&D). FDA briefing documents noted that “the treatment paradigm evaluated in SERENA-6 is new” and that “currently, no drugs have FDA approval for switching treatment in patients based on detection.” Analysts like Bernstein trimmed their target price but kept the stock as a top pick; JPMorgan called the outcome a “minor negative,” noting camizestrant would represent about 1 % of valuation.

CNBC

Panelists argued the early-switch design lacks evidence of long-term overall-survival benefit and could set a precedent for future trials. They noted the lack of mature OS data and limited quality-of-life information, warning that switching before radiographic progression may not improve outcomes.

BioSpace

While the ODAC panel found SERENA-6 data insufficient to change practice, analysts say the drug could still gain approval from other studies. Immature OS data create uncertainty about long-term benefit, and regulators have not clarified whether the early-switch approach will be accepted.

CNBC

• “The data for changing the paradigm just isn’t there,” — Stanley Lipkowitz, Deputy Director, Center for Cancer Research, National Cancer Institute

BioSpace

• “If there were an OS [overall survival] benefit, I would have voted yes,” — Stanley Lipkowitz

BioSpace

• “But I really wonder if we are exploiting the hope of women with metastatic breast cancer,” — Natalie Compagni Portis, Patient Representative

BioSpace

• “the treatment paradigm evaluated in SERENA-6 is new.” — FDA internal reviewer (briefing document)

BioSpace

• “Currently, no drugs have FDA approval for switching treatment in patients based on detection” — FDA internal reviewer (briefing document)

BioSpace

The panel’s rejection threatens a growth driver AstraZeneca expects to add up to $5 billion in peak sales toward its $80 billion 2030 target. A precedent on early-switch trial designs could reshape oncology development and regulatory expectations. Analysts view the impact as limited—citing camizestrant’s modest share of valuation—though investor sentiment may soften after the 2.5 % share-price dip.

Reuters

The FDA is expected to issue a final decision later in 2026, possibly using data from other camizestrant studies. AstraZeneca will keep testing the drug in additional breast-cancer settings while advancing its pipeline of up to 20 launches. Market watchers will track the 2026 readouts for clues on the drug’s regulatory trajectory.

CNBC